comparemela.com

Latest Breaking News On - He okyo gg00bd3fv870 - Page 1 : comparemela.com

Notice of General Meeting and Publication of Circular

LONDON and NEW YORK, April 05, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | April 5, 2023

City ofUnited kingdomUnited statesRobert emmetGarys jacobPaul spencerList of the financial conduct authorityPharma limited nasdaqPharma limitedLondon stock exchangeHerrington sutcliffe united kingdomOptiva securitiesOfficial listFinancial conduct authorityOrdinary sharesAmerican depositary share

Notice of Intention to Delist From The London Stock Exchange

LONDON and NEW YORK, April 04, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | April 4, 2023

City ofUnited kingdomRobert emmetGarys jacobKeeren shahPaul spencerPharma limited nasdaqUnited kingdom financial conduct authorityLondon stock exchangeCompany american depositary shares adssOptiva securitiesPharma limitedAmerican depositary sharesOrdinary sharesMain marketListing rule

OKYO Pharma Today Announces Director Acquires Shares

LONDON and NEW YORK, March 29, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | March 29, 2023

United kingdomCity ofRobert emmetPaul spencerGabriele cerroneGarys jacobPharma limitedCompany adssOptiva securitiesPanetta partnersPharma limited nasdaqLondon stock exchangePanetta partners limitedExecutive chairmanChief executiveOfficial list

OKYO Pharma Announces PDMR Dealing | MarketScreener

LONDON and NEW YORK, March 24, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | March 24, 2023

United kingdomCity ofRobert emmetGabriele cerronePaul spencerGarys jacobPanetta partnersOptiva securitiesLondon stock exchangePharma limitedPharma limited nasdaqCompany adssPanetta partners limitedExecutive chairmanChief executiveOfficial list

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials gov Public Website

LONDON and NEW YORK, March 16, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | March 16, 2023

United kingdomCity ofPaul spencerGarys jacobPharma ltdLondon stock exchangePharma limitedOptiva securitiesOfficial listUnited kingdom financial conduct authorityChief executive officerChief executiveOkyo pharma limited stock exchangePress releaseHe okyo gg00bd3fv870

vimarsana © 2020. All Rights Reserved.